EMA Application withdrawn: Zunrisa (casopitant) — Glaxo Group Ltd

View source ↗

Summary

The EMA withdrew the application for Zunrisa (casopitant) from Glaxo Group Ltd for indications in vomiting, postoperative nausea and vomiting, and cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Postoperative Nausea and Vomiting
• Vomiting

Drugs mentioned

• Zunrisa (casopitant mesilate)

Snippet

Status: Application withdrawn. Therapeutic area: Vomiting;Postoperative Nausea and Vomiting;Cancer. MAH: Glaxo Group Ltd. Decision date: 31/12/2009